Atea Pharmaceuticals Tangible Assets Book Value per Share Trend from 2010 to 2021

AVIR -  USA Stock  

USD 25.04  0.69  2.83%

Atea Pharmaceuticals Tangible Assets Book Value per Share yearly trend continues to be relatively stable with very little volatility. Tangible Assets Book Value per Share are likely to grow to 43.16 this year. During the period from 2010 to 2021, Atea Pharmaceuticals Tangible Assets Book Value per Share destribution of quarterly values had range of  40.97 from its regression line and mean deviation of  10.62. As of 08/01/2021, Direct Expenses is likely to grow to about 1.4 M.

Search Historical Trends 

 
Refresh
Check Atea Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Atea Pharmaceuticals main balance sheet or income statement drivers, such as Direct Expenses of 1.4 M, Gross Profit of 43.5 M or Operating Expenses of 47.6 M, as well as many exotic indicators such as Long Term Debt to Equity of 0.0077, PPandE Turnover of 42.93 or Receivables Turnover of 13.11. Atea Pharmaceuticals financial statements analysis is a perfect complement when working with Atea Pharmaceuticals Valuation or Volatility modules. It can also supplement various Atea Pharmaceuticals Technical models. Please continue to the analysis of Atea Pharmaceuticals Correlation against competitors.

Atea Pharmaceuticals Tangible Assets Book Value per Share Breakdown

Showing smoothed Tangible Assets Book Value per Share of Atea Pharmaceuticals with missing and latest data points interpolated. Measures the ratio between Tangible Asset Value and [SharesWA] as adjusted by [ShareFactor].Atea Pharmaceuticals' Tangible Assets Book Value per Share historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Atea Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Tangible Assets Book Value per Share10 Years Trend
Increasing
Slightly volatile
 Tangible Assets Book Value per Share 
Share
      Timeline 

Atea Pharmaceuticals Tangible Assets Book Value per Share Regression Statistics

Arithmetic Mean 9.72
Geometric Mean 5.05
Coefficient Of Variation 153.38
Mean Deviation 10.62
Median 3.47
Standard Deviation 14.90
Sample Variance 222.07
Range 40.97
R-Value 0.64
Mean Square Error 144.29
R-Squared 0.41
Significance 0.025058
Slope 2.64
Total Sum of Squares 2,443

Atea Pharmaceuticals Tangible Assets Book Value per Share History

2019  2.19 
2020  40.00 
2021  43.16 

About Atea Pharmaceuticals Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Atea Pharmaceuticals income statement, its balance sheet, and the statement of cash flows. Atea Pharmaceuticals investors use historical funamental indicators, such as Atea Pharmaceuticals's Tangible Assets Book Value per Share, to determine how well the company is positioned to perform in the future. Although Atea Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Atea Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Atea Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Atea Pharmaceuticals Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Atea Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2021
Tangible Assets Book Value per Share 40.00  43.16 
Tangible Asset Value863.6 M931.8 M
Average Assets442.9 M369.5 M
Enterprise ValueBB
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. The company was incorporated in 2012 and is headquartered in Boston, Massachusetts. Atea Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Atea Pharmaceuticals without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Portfolio File Import Now

   

Portfolio File Import

Quickly import all of your third-party portfolios from your local drive in csv format
All  Next Launch Module

Pair Trading with Atea Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Atea Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Atea Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Atea Pharmaceuticals Pair Correlation

Equities Pair Trading Analysis

Please continue to the analysis of Atea Pharmaceuticals Correlation against competitors. Note that the Atea Pharmaceuticals information on this page should be used as a complementary analysis to other Atea Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Shere Portfolio module to track or share privately all of your investments from the convenience of any device.

Complementary Tools for Atea Pharmaceuticals Stock analysis

When running Atea Pharmaceuticals price analysis, check to measure Atea Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atea Pharmaceuticals is operating at the current time. Most of Atea Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Atea Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Atea Pharmaceuticals' price. Additionally, you may evaluate how the addition of Atea Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Go
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
The market value of Atea Pharmaceuticals is measured differently than its book value, which is the value of Atea Pharmaceuticals that is recorded on the company's balance sheet. Investors also form their own opinion of Atea Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Atea Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Atea Pharmaceuticals' market value can be influenced by many factors that don't directly affect Atea Pharmaceuticals underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Atea Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Atea Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Atea Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.